Biosimilar Pipeline Analysis: Current Biosimilar Landscape Additionally, adalimumab biosimilar pipeline analysis seem well positioned for launch as the first adalimumab biosimilar was approved in the EU in 2018. At least ten adalimumab biosimilar applications are approved or under review globally. These represent some of the most valuable opportunities in the biosimilar space given adalimumab's billions in annual sales. Get More Insights On Biosimilar Pipeline Analysis #Biosimilars, #PipelineAnalysis, #Biopharmaceuticals, #MarketTrends, #DrugDevelopment, #RegulatoryAffairs, #CoherentMarketInsights